http://finance.yahoo.com/q/hp?s=AEMD.OB

16-Mar-04 1.90 2.00 1.40 1.50 101,958 1.50
15-Mar-04 2.10 2.10 1.90 2.00 44,445 2.00
12-Mar-04 1.80 2.18 1.80 2.05 58,993 2.05
11-Mar-04 2.20 2.20 1.80 1.85 28,495 1.85
10-Mar-04 2.75 2.75 2.01 2.15 133,630 2.15
9-Mar-04 1.05 4.25 1.01 2.55 298,944 2.55
8-Mar-04 0.85 1.05 0.85 1.05 20,000 1.05
5-Mar-04 0.70 0.83 0.70 0.83 6,200 0.83
4-Mar-04 0.75 0.95 0.75 0.85 8,000 0.85
3-Mar-04 0.75 0.75 0.75 0.75 1,223 0.75
2-Mar-04 0.75 0.75 0.75 0.75 100 0.75
1-Mar-04 0.60 0.75 0.60 0.75 5,000 0.75
27-Feb-04 0.41 0.41 0.41 0.41 0 0.41
26-Feb-04 0.41 0.41 0.41 0.41 0 0.41
25-Feb-04 0.41 0.41 0.41 0.41 350 0.41
24-Feb-04 0.45 0.60 0.45 0.60 3,700 0.60

NEWS http://finance.yahoo.com/q/h?s=AEMD.OB
http://biz.yahoo.com/bw/040312/125314_1.html

Aethlon Medical Announces Conference Presentations and Research Coverage
SAN DIEGO--(BUSINESS WIRE)--March 12, 2004--Aethlon Medical, Inc. (OTCBB:AEMD - News) announced today that its Chairman and CEO, Mr. James A. Joyce will be a featured presenter at the Investment Opportunities in Homeland Defense and Security Conference, to be held at the National Press Club in Washington D.C. on March 30, 2004. Archived streaming audio of the presentation will be available on the web at: www.domesticpreparedness.com. Additionally, Mr. Joyce is scheduled to present at the Growth Capital Conference XII to be held at The Olympic Collection in Los Angeles on April 1, 2004. Information available at: www.gcc2000.org
http://biz.yahoo.com/bw/040304/45307_1.html
Aethlon Medical Announces National Center for Biodefense Agreement
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=AEMD&script=2100
READ THIS... FIRST PARAGRAPH REALLY GOT ME REALED IN...
Corporate Profile

Aethlon Medical develops therapeutic devices that treat HIV/AIDS, Hepatitis-C, and other infectious diseases. In pre-clinical testing, Aethlon’s lead product, AEMD-45 removes 55% of HIV from human blood in three hours and in excess of 85% in twelve hours.

AEMD-45 therapeutic device, like all product offerings from Aethlon Medical, is developed from an expansive platform technology known as the HemopurifierTM, which employs a proprietary method of modifying artificial kidneys (hemodialysis cartridges) to mimic the immune systems response to clear infectious virus from circulation before healthy cells can be infected. AEMD-45 is designed to fill the urgent need for new treatments that are effective in reducing viral load, decrease the likelihood of treatment resistance, and treat without the side effects of current AIDS drugs. Based on recent human blood studies, AEMD-45 serves as a promising new weapon to combat AIDS, and is well positioned to treat the full-spectrum of HIV-infected individuals.

As conjunctive therapy to enhance and prolong the performance of established pharmaceutical regimens.

As a treatment for the large and growing population of HIV infected that have either become drug resistant or are unable to tolerate drug therapy.

As a treatment for dialysis patients that are co-infected with HIV.

As a front line treatment for newly infected individuals who are delaying treatment with AIDS drugs, as advised under new federal guidelines.

Aethlon Industry Coverage

The HIV-Hemopurifier technology has been the subject of increased media coverage, including articles in United Press International, New Scientist Magazine, BioWorld, AIDS Weekly, and a television feature on CNNfn. A recent article in The Chicago Tribune and The Washington Times named Aethlon Medical, along with Trimeris, Inc. (TRMS) and Progenics (PGNX) to be the leaders in the “Entry Inhibitor” segment for treating AIDS, and in the “Immunology” sector, Aethlon Medical was again named a leader along with Chiron (CHIR) and Hollis-Eden Pharmaceuticals (HEPH).

Technology Investor Magazine stated: “By reducing viral load and removing mutant strains of HIV without interfering with existing therapy, the HIV-Hemopurifier has the potential to be used either by itself or as a way to prolong the life of some antivirals on the market now. If used at the outset of the disease, it has the potential to prolong the time before a patient has to resort to drug therapy.”

Industry Background / Issues

The size of the HIV market is expected to triple by 2007, with sales of antiretroviral drugs growing from $5 billion in 2001 to over $13 billion by 2007. Compounding the rapid spread of the disease, researchers project that the share of HIV infections that are drug-resistant will grow from a current rate of 28.5% to 42% by 2005. In the absence of therapeutic intervention, the vast majority of individuals infected with HIV ultimately develop AIDS, which has a mortality rate approaching 100%. Since AIDS was discovered in 1981, there have been few breakthroughs in the effort to cure this progressive and fatal disease. Since the epidemic began, 57 million people have become infected with the AIDS virus and more than 21 million people have died. In the year 2000, there were 3 million AIDS related deaths (almost 9,000 deaths per day). Of the 36 million infected with HIV, the AIDS virus, 5.3 million were new cases.

Recognizing the severity of the issue, The White House has declared AIDS to be a National Security Issue. It is the first time an infectious disease has been added to a list of security threats that includes terrorism and weapons of mass destruction. The Wall Street Journal projects the population of those infected with the AIDS virus will exceed 100 million in the year 2005.

New Federal Treatment Guidelines

Citing dangerous side effects and issues of drug resistance, the federal government changed its AIDS treatment policy on February 5, 2001, stating that HIV-infected people should now allow for a further progression of the disease before initiating drug regimens. The prior recommendations of “hit early, hit hard” with available drug regimens were originally issued five years ago. The new guidelines suggest that practitioners should now withhold treating HIV-infected people with available drugs until their supply of T-helper cells drops to just 350 per cubic millimeter of blood. As a non-pharmaceutical product, the HIV-Hemopurifier is well positioned to become an important therapy to reduce viral load and improve the quality of life for those patients that are left with no treatment options while waiting to initiate drug therapy.

The Aethlon HIV-HemopurifierTM

As with other products in the Aethlon technology portfolio, the basis of each HIV-HemopurifierTM is a modified dialysis cartridge containing approximately 10,000 hollow fibers and immobilized compounds that create an affinity matrix, which binds viruses or toxins circulating in the blood. As the patient’s blood passes through each fiber, viruses and toxins pass through the pores in the fiber walls and are bound within the affinity matrix. Blood cells and platelets remain within the fibers and are safely returned back into circulation. The advantages of Hemopurifier treatments are:

A rapid reduction of viral load without the side effects of drug treatments.
Assists the immune function by binding harmful viral proteins.
Reduces the likelihood of drug resistance.
Designed for use in over 10,000 established dialysis centers.
Value Added Services

Since the HIV-Hemopurifier effectively concentrates HIV and harmful viral proteins from the entire bloodstream during treatment, the detection sensitivity of current diagnostic tests can be enhanced as much as 1000-fold. As a result, Aethlon will contract with leading diagnostic organizations to offer physicians with the following value services in addition to the benefit of treatment:

Measurement of the amount of HIV removed from the body.
Measurement of the amount of harmful viral proteins removed from the body.
Isolate and identify viral strains so that pharmaceutical regimens can be “tailored” to eliminate the use of drugs to which the strains are resistant.
Technology Portfolio

Corporate Profile

Aethlon Medical develops therapeutic devices that treat HIV/AIDS, Hepatitis-C, and other infectious diseases. In pre-clinical testing, Aethlon’s lead product, AEMD-45 removes 55% of HIV from human blood in three hours and in excess of 85% in twelve hours.

AEMD-45 therapeutic device, like all product offerings from Aethlon Medical, is developed from an expansive platform technology known as the HemopurifierTM, which employs a proprietary method of modifying artificial kidneys (hemodialysis cartridges) to mimic the immune systems response to clear infectious virus from circulation before healthy cells can be infected. AEMD-45 is designed to fill the urgent need for new treatments that are effective in reducing viral load, decrease the likelihood of treatment resistance, and treat without the side effects of current AIDS drugs. Based on recent human blood studies, AEMD-45 serves as a promising new weapon to combat AIDS, and is well positioned to treat the full-spectrum of HIV-infected individuals.

As conjunctive therapy to enhance and prolong the performance of established pharmaceutical regimens.

As a treatment for the large and growing population of HIV infected that have either become drug resistant or are unable to tolerate drug therapy.

As a treatment for dialysis patients that are co-infected with HIV.

As a front line treatment for newly infected individuals who are delaying treatment with AIDS drugs, as advised under new federal guidelines.

Aethlon Industry Coverage

The HIV-Hemopurifier technology has been the subject of increased media coverage, including articles in United Press International, New Scientist Magazine, BioWorld, AIDS Weekly, and a television feature on CNNfn. A recent article in The Chicago Tribune and The Washington Times named Aethlon Medical, along with Trimeris, Inc. (TRMS) and Progenics (PGNX) to be the leaders in the “Entry Inhibitor” segment for treating AIDS, and in the “Immunology” sector, Aethlon Medical was again named a leader along with Chiron (CHIR) and Hollis-Eden Pharmaceuticals (HEPH).

Technology Investor Magazine stated: “By reducing viral load and removing mutant strains of HIV without interfering with existing therapy, the HIV-Hemopurifier has the potential to be used either by itself or as a way to prolong the life of some antivirals on the market now. If used at the outset of the disease, it has the potential to prolong the time before a patient has to resort to drug therapy.”

Industry Background / Issues

The size of the HIV market is expected to triple by 2007, with sales of antiretroviral drugs growing from $5 billion in 2001 to over $13 billion by 2007. Compounding the rapid spread of the disease, researchers project that the share of HIV infections that are drug-resistant will grow from a current rate of 28.5% to 42% by 2005. In the absence of therapeutic intervention, the vast majority of individuals infected with HIV ultimately develop AIDS, which has a mortality rate approaching 100%. Since AIDS was discovered in 1981, there have been few breakthroughs in the effort to cure this progressive and fatal disease. Since the epidemic began, 57 million people have become infected with the AIDS virus and more than 21 million people have died. In the year 2000, there were 3 million AIDS related deaths (almost 9,000 deaths per day). Of the 36 million infected with HIV, the AIDS virus, 5.3 million were new cases.

Recognizing the severity of the issue, The White House has declared AIDS to be a National Security Issue. It is the first time an infectious disease has been added to a list of security threats that includes terrorism and weapons of mass destruction. The Wall Street Journal projects the population of those infected with the AIDS virus will exceed 100 million in the year 2005.

New Federal Treatment Guidelines

Citing dangerous side effects and issues of drug resistance, the federal government changed its AIDS treatment policy on February 5, 2001, stating that HIV-infected people should now allow for a further progression of the disease before initiating drug regimens. The prior recommendations of “hit early, hit hard” with available drug regimens were originally issued five years ago. The new guidelines suggest that practitioners should now withhold treating HIV-infected people with available drugs until their supply of T-helper cells drops to just 350 per cubic millimeter of blood. As a non-pharmaceutical product, the HIV-Hemopurifier is well positioned to become an important therapy to reduce viral load and improve the quality of life for those patients that are left with no treatment options while waiting to initiate drug therapy.

The Aethlon HIV-HemopurifierTM

As with other products in the Aethlon technology portfolio, the basis of each HIV-HemopurifierTM is a modified dialysis cartridge containing approximately 10,000 hollow fibers and immobilized compounds that create an affinity matrix, which binds viruses or toxins circulating in the blood. As the patient’s blood passes through each fiber, viruses and toxins pass through the pores in the fiber walls and are bound within the affinity matrix. Blood cells and platelets remain within the fibers and are safely returned back into circulation. The advantages of Hemopurifier treatments are:

MRKL I bought at 1.19 and sold at 2.04, then bought again at 1.24 and sold at 1.65.
NOW sold out..

BLLD bought 1.28 sold at 1.74..

AEMD. Just BOUGHT at 1.50 and 1.35 and will buy as long as i can at these prices..

This one however i may go long on. I like how it popped from .75 cents to 4.25 on 300K volume a week ago.

That was some news, Looks like it retraced quite a bit and looks attractive once again.

SO now im buying in since i missed the first run..

MY bet says, alot of new investors will be running to get in on this throughout next week.

SO i plan on buying this week, while its still under 2 bucks..

No matter what price....

I have talked to alot of friends and they all agree this could be a big one.

That first paragraph in their company website says alot, and then the biodeffense agreement, really got me in...

Im surprised no one knows about this yet.

Wait until volume is a few hundred thousand everyday.. This thing will move so fast.

IF mddm can go to 5.20,
I think AEMD.ob which is a bulletin board and not a pink like mddm, and

has an even smaller float than all the rest can go higher.

These are my opinions of course, but anyone can se my logic....

Take a look at this.. ANd tell me what you think..

IM going in deep on this one..

SO far i have 8K shares.. av price around 1.50 after commissions....

That means alot more attacks, and money will be pooring in to homeland security by the govt.

As sad as it is, this is the truth.

I hate all the bombings, and all the terror, but it is really getting bad again.

And as an investor, im figuring this is where the money is.. TO COMBAT EVIL....

GET RID OF ALL THESE GUYS... LOCK EM ALL UP..

and i like this also..

"We are developing wearable devices that can be deployed by our armed forces as a post-exposure therapeutic during battlefield events, as well as dialysis based treatments for civilian populations," stated James A. Joyce, chairman and CEO of Aethlon Medical.

masters

Listen to the interview with CNN...

They are pushing their product through to FDA approval. Might not have to do human trials. They stated, it could be accepted on just animal trials..

My opinions -- from what i read and perception. Double check me...

But thats what i recall..

DEVELOPENTAL PHASE COMPANY -- means no revenues until they get products to market.

BUT this is when the stock is still cheap.

SIZE

GNET 10 on bid NITE on ask 5..

In after hours. Very odd.

Says he expects FDA approval sometime between 24-36 months out.

The interview was on May 11, 2001.

That would mean we are approx 34 months out from the interview.

SO -- FDA APPROVAL CAN BE ALMOST ANY DAY NOW.